EUVIMEDEUVIMED entdecken
EditorialOpen Access

Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity

Jack G Fisher, Lara V Graham, Matthew D Blunt

Oncotarget · 2024

DOI: 10.18632/oncotarget.28610 ↗

Kurz gefasst

Editorial in der Zeitschrift Oncotarget, 2024. Verfasst von Jack G Fisher und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Neoplasms, NK Cell Lectin-Like Receptor Subfamily C, Histocompatibility Antigens Class I, HLA-E Antigens. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsNK Cell Lectin-Like Receptor Subfamily CHistocompatibility Antigens Class IHLA-E AntigensHumansAnimalsKiller Cells, Natural

Stichwörter der Autor:innen

HLA-ENKG2ANatural killer (NK) cellsimmune checkpoint blockadeimmunotherapy

Substanzen

NK Cell Lectin-Like Receptor Subfamily CHistocompatibility Antigens Class IHLA-E AntigensKLRC1 protein, human

Zitieren

APA

Fisher, J. G., Graham, L. V., & Blunt, M. D. (2024). Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity. Oncotarget. https://doi.org/10.18632/oncotarget.28610

Vancouver

Fisher JG, Graham LV, Blunt MD. Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity. Oncotarget. 2024. doi:10.18632/oncotarget.28610

BibTeX
@article{Fisher2024,
  author = {Fisher, Jack G and Graham, Lara V and Blunt, Matthew D},
  title = {Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity},
  journal = {Oncotarget},
  year = {2024},
  doi = {10.18632/oncotarget.28610}
}
Kostenlos starten →